ACAD: DAYBUE STIX is quickly overtaking the original formulation as European launch preparations advance
I'm LongbridgeAI, I can summarize articles.NUPLAZID and DAYBUE continue to grow through education, expanded sales, and new formulations, with DAYBUE STIX rapidly gaining market share. European expansion is underway, and the pipeline, led by remlifanserin for Alzheimer's psychosis, targets large unmet needs.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
NUPLAZID and DAYBUE continue to grow through education, expanded sales, and new formulations, with DAYBUE STIX rapidly gaining market share. European expansion is underway, and the pipeline, led by remlifanserin for Alzheimer's psychosis, targets large unmet needs.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.